Shots:
- Alnylam Pharmaceuticals & Inceptive Nucleics have entered into a strategic collaboration to accelerate the discovery of novel RNAi therapeutics
- The collaboration is valued at up to $2B, with $30M upfront, incl. cash & an equity investment in Inceptive. Inceptive will also receive additional preclinical, regulatory, & commercial milestone payments
- Collaboration combines Alnylam’s RNAi expertise & siRNA dataset from over 20yrs. of research, with Inceptive’s AI-powered foundation models for sequence-based medicines to accelerate the design and development of nucleic acid therapeutics
Ref: Businesswire | Image: Alnylam and Inceptive | Press Release
Related News: Tenaya Therapeutics and Alnylam Pharmaceuticals Partner to Discover Novel Genetic Targets for CV Therapies in ~$1.13B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
